What kind of company is watson biological?

Watson biological was founded on 200 1, headquartered in Kunming, Yunnan Province, and listed on the Growth Enterprise Market of Shenzhen Stock Exchange on 2010/1. The company is a high-tech biopharmaceutical company specializing in the research, development, production and sales of biotechnological drugs such as human vaccines, and has two major vaccine varieties in the world, namely 13 valent pneumonia conjugate vaccine and HPV vaccine.

Watson biological (full name: Yunnan watson biological Technology Co., Ltd.) is a biopharmaceutical enterprise in China, a nationally recognized high-tech enterprise and a national enterprise technology center.

The company specializes in research and development, production and sales of biopharmaceuticals such as vaccines for human use and blood products, and was listed on the Growth Enterprise Market of Shenzhen Stock Exchange on 20101.

June 65438+1October 65438+September 2022, Hurun China Top 500 was released, and watson biological ranked 148 with 99 billion yuan.

Enterprise profile

The company has advanced new vaccine R&D center and pilot base in Kunming National High-tech Zone, modern vaccine production base in Yuxi High-tech Zone in Taizhou, Jiangsu Province and China Medical City, and its marketing network covers many provinces, cities and counties in China.

2010165438+1October 12 and Yunnan watson biological science and technology co., ltd (stock abbreviation: watson biological stock code: 300 142) were successfully listed on Shenzhen Stock Exchange, becoming the first enterprises in Yunnan Province to be listed on China Growth Enterprise Market.

Enterprise product

The company is in a leading position in vaccine research and development. Up to now, 13 vaccine products have been successfully developed, with broad market prospects and nearly 20 products under research. Among them, Haemophilus influenzae type B conjugate vaccine and freeze-dried meningococcal polysaccharide conjugate vaccine have been put on the market and achieved good results. In addition, six products have completed clinical research and obtained clinical research qualification reports. The production workshops of freeze-dried A, C, Y, W 135 meningococcal polysaccharide vaccine and freeze-dried A and C meningococcal polysaccharide vaccine have been completed and passed the trial production, and the application for drug production approval will be put on the market soon.

However, the cell-free DTP triple vaccine production line has been completed and is in the trial production stage. The workshop for the production of split influenza vaccine for children and adults has entered the construction stage. The follow-up product workshop is being planned and designed.

From 20 1 1, with the maturity of a large number of reserved products, the company will enter a new round of peak production and construction of new products. Due to the subsequent launch of a large number of new products, watson biological's business performance will also usher in a new round of climb.